News
PBRM1 mutations not quite up to snuff as ccRCC biomarkers
Truncating mutations in PBRM1 are moderately linked to response to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.
News
Many experimental drugs veer off course when targeting cancer
Ten anticancer drugs in development target proteins that are not essential for the survival or growth of cancer cells, investigators caution.
News
HER2-mutant NSCLC confers high brain metastases risk
Patients with HER2-mutated non–small cell lung cancer were more likely to develop brain metastases on therapy than patients with KRAS mutations....
News
Protons safe, effective for breast cancer control
Toxicity and disease control rates with proton-beam therapy to treat internal mammary nodes compared favorably with those of conventional...
News
Tandem transplants provide EFS edge in pediatric neuroblastoma
Patients randomized to tandem stem cell transplants after successful induction therapy had fewer events than patients assigned to single...
News
Molecular profiling a must in advanced NSCLC
Identification of targetable mutations and the advent of immune checkpoint inhibitors have improved outcomes for many patients.
News
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
LUGANO, SWITZERLAND – In patients younger than 65 years old, two cycles of ibrutinib and rituximab followed by four cycles of chemotherapy...
News
Diet, exercise don’t improve breast cancer-related lymphedema
There were no significant differences in limb volume changes among overweight women with lymphedema 1 year after starting a lifestyle intervention...
News
EHR-derived data on tumor progression may predict survival
Real-world data on NSCLC progression drawn from electronic charts correlated with overall survival.
News
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71...
News
HDAC/HMA combo shows ‘remarkable’ activity in PTCL
LUGANO, SWITZERLAND – Patients with AITL and PTCL-TFH subtypes had high overall response rates to romidepsin and AZA.
News
Bevacizumab or pemetrexed, but not both, efficacious for NSCLC maintenance
The combination of bevacizumab and pemetrexed did not improve survival and had significantly worse toxicity than bevacizumab alone.
News
High EPclin score equals chemo benefit in ER+/HER2– breast cancer
Women with high EPclin scores would be likely to have an absolute benefit from chemotherapy added to endocrine therapy, a mathematical model...
News
ctDNA may predict relapse risk in early breast cancer
Circulating tumor DNA was associated with a significant risk for relapse in women treated for early primary breast cancers.